Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Vivos Therapeutics (VVOS) Loans and Notes Receivables (2019 - 2021)

Vivos Therapeutics (VVOS) has disclosed Loans and Notes Receivables for 3 consecutive years, with $61864.0 as the latest value for Q3 2021.

  • On a quarterly basis, Loans and Notes Receivables changed N/A to $61864.0 in Q3 2021 year-over-year; TTM through Sep 2021 was $61864.0, a N/A change, with the full-year FY2020 number at $84000.0, down 0.82% from a year prior.
  • Loans and Notes Receivables was $61864.0 for Q3 2021 at Vivos Therapeutics, up from $56732.0 in the prior quarter.
  • In the past five years, Loans and Notes Receivables ranged from a high of $84696.0 in Q4 2019 to a low of $56732.0 in Q2 2021.
  • A 3-year average of $74397.6 and a median of $84000.0 in 2020 define the central range for Loans and Notes Receivables.
  • Biggest YoY gain for Loans and Notes Receivables was 0.82% in 2020; the steepest drop was 0.82% in 2020.
  • Vivos Therapeutics' Loans and Notes Receivables stood at $84696.0 in 2019, then decreased by 0.82% to $84000.0 in 2020, then fell by 26.35% to $61864.0 in 2021.
  • Per Business Quant, the three most recent readings for VVOS's Loans and Notes Receivables are $61864.0 (Q3 2021), $56732.0 (Q2 2021), and $84696.0 (Q1 2021).